Barw Medical Journal
Submit your article

Review Articles Barw Medical Journal. 2023

Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature

, , , , , , , , , , , , , , , , , ,

Sami S. Omar

  • 1Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq

9 articles in this journal

Rebaz Haji Ali

  • 2Hiwa Cancer Hospital. Sulaymaniyah, Kurdistan, Iraq

3 articles in this journal

Shalaw H. Abdullah

  • 2Hiwa Cancer Hospital. Sulaymaniyah, Kurdistan, Iraq

Dlsoz M. Hussein

  • 3Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

6 articles in this journal

Belan Mikaeil M. Radha

  • 4College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

Alaa B. Latif

  • 4College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

2 articles in this journal

Shano M. Ali

  • 2Hiwa Cancer Hospital. Sulaymaniyah, Kurdistan, Iraq

5 articles in this journal

Dilan S. Hiwa

  • 3Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

13 articles in this journal

Harem K. Ahmed

  • 5Department of Medicine, Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq

8 articles in this journal

Ahmed G. Hamasaeed

  • 6Faculty of Medical Sciences, School of Pharmacy, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq

Snur Othman

  • 7Maternity and Children Hospital, Halabja, Sulaymaniyah, Kurdistan, Iraq

8 articles in this journal

Shevan M. Mustafa

  • 8Department of Forensic Sciences, College of science, Al-Kitab University, Kirkuk, Iraq

4 articles in this journal

Diyar A. Omar

  • 9Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Iraq

9 articles in this journal

Dahat A. Hussein

  • 3Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

44 articles in this journal

Suhaib H. Kakamd

  • 10Collage of Medicine, Department of Immunology and Hematology. Kurdistan University of Medical Science, Sanandaj, Iran

2 articles in this journal

Marwan N. Hassan

  • 3Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

26 articles in this journal

Hawbash M. Rahim

  • 11Medical Laboratory Science Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Kurdistan Region, Iraq

17 articles in this journal

Berun A. Abdalla

  • 12Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

61 articles in this journal

Fahmi H. kakamad

  • 4College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

Corresponding author

63 articles in this journal

  • 1Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq
  • 2Hiwa Cancer Hospital. Sulaymaniyah, Kurdistan, Iraq
  • 3Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
  • 4College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
  • 5Department of Medicine, Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq
  • 6Faculty of Medical Sciences, School of Pharmacy, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
  • 7Maternity and Children Hospital, Halabja, Sulaymaniyah, Kurdistan, Iraq
  • 8Department of Forensic Sciences, College of science, Al-Kitab University, Kirkuk, Iraq
  • 9Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Iraq
  • 10Collage of Medicine, Department of Immunology and Hematology. Kurdistan University of Medical Science, Sanandaj, Iran
  • 11Medical Laboratory Science Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Kurdistan Region, Iraq
  • 12Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

Corresponding author: [email protected] (Fahmi H. kakamad)

Submitted
25 Oct 2023
Accepted
17 Feb 2024
Published
5 Dec 2023
Reads
854
Downloads
642
Citations
1 Citations are Crossref’s count on 8 November 2026.

doi:10.58742/peq00z60 Open access CC BY 4.0 licence (opens in a new tab)

Download PDF XML

Abstract

Introduction
Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or not bevacizumab is administered. Immunotherapy-based immune checkpoint inhibitors demonstrated a promising antitumor efficacy in a variety of cancer types. This is a systematic review of the current role of durvalumab in the management of this condition.

Methods
A systematic search was carried out through the databases and search engines. Regardless of study design, line of therapy, mode of therapy, or Eastern Cooperative Oncology Group (ECOG) performance status, studies that primarily focused on the outcomes of treating this disease with durvalumab were eligible for inclusion. After the initial and full-text screenings, five studies were reviewed.

Results
The median age of the total 235 patients was 66.9 years. Males comprised 174 (74.04%) of the cases, with 61 (25.95%) cases being female. The Epithelioid mesothelioma subtype accounted for 194 (82.55%) of the patients. Durvalumab, in combination with pemetrexed cisplatin/carboplatin as therapy, was used in 109 (48.38%) cases. Durvalumab and tremelimumab were used in the treatment of 40 (17.02%) cases, of which 17 (7.23%) had retreatment with both immunotherapies. Among the patients who underwent durvalumab treatment, 69 (29.36% ) of the individuals previously received carboplatin/pemetrexed and cisplatin/pemetrexed.

Conclusion
Durvalumab can be utilized as an effective alternative for malignant pleural mesothelioma treatment, providing positive results and acceptable safety profiles.

Keywords Durvalumab Immune checkpoint inhibitors Malignant mesothelioma Second line Immunotherapy All subjects

Sections3

The full text is in the PDF of record

This article was published as a typeset PDF and XML. The abstract above is the version of record’s own summary; the complete text, its figures, its tables and its reference list are in the files below.

Read the PDF XML
Citable now
Barw Medical Journal. 2023
Where it sits

References22

  1. Calabrò, L., et al., Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. The Lancet Respiratory Medicine, 2021. 9(9): p. 969-976. doi:10.1016/S2213-2600(21)00043-6

    10.1016/S2213-2600(21)00043-6CrossrefPubMedScopusGoogle Scholar

  2. Ahmadzada, T., et al., Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical and Research Reports, 2020. 1(4): p. 100075. doi:10.1016/j.jtocrr.2020.100075

    10.1016/j.jtocrr.2020.100075CrossrefPubMedScopusGoogle Scholar

  3. Forde, P.M., et al., Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine, 2021. 27(11): p. 1910-1920. doi:10.1038/s41591-021-01541-0

    10.1038/s41591-021-01541-0CrossrefPubMedScopusGoogle Scholar

  4. Arru, C., et al., Durvalumab plus tremelimumab in solid tumors: A systematic review. Advances in Therapy, 2021. 38(7): p. 3674-3693. doi:10.1007/s12325-021-01796-6

    10.1007/s12325-021-01796-6CrossrefPubMedScopusGoogle Scholar

  5. Canova, S., et al., Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. ESMO open, 2022. 7(6): p. 100644. doi:10.1016/j.esmoop.2022.100644

    10.1016/j.esmoop.2022.100644CrossrefPubMedScopusGoogle Scholar

  6. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2016;387(10026):1405-14. doi:10.1016/S0140-6736(15)01238-6

    10.1016/S0140-6736(15)01238-6CrossrefPubMedScopusGoogle Scholar

  7. Nowak, A.K., et al., Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 2020. 21(9): p. 1213-1223. doi:10.1016/S1470-2045(20)30462-9

    10.1016/S1470-2045(20)30462-9CrossrefPubMedScopusGoogle Scholar

  8. Ferris, R., et al., Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Annals of Oncology, 2020. 31(7): p. 942-950. doi:10.1016/j.annonc.2020.04.001

    10.1016/j.annonc.2020.04.001CrossrefPubMedScopusGoogle Scholar

  9. Muhialdeen, A.S., et al., Kscien’s List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version). Barw Medical Journal, 2023. doi:10.58742/bmj.v1i1.14

    10.58742/bmj.v1i1.14CrossrefPubMedScopusGoogle Scholar

  10. Ali, R.M., et al., Pembrolizumab (Anti-PD-1) in the management of malignant pleural mesothelioma: A systematic review of the current literature. Barw Medical Journal, 2023. doi:10.58742/bmj.v1i2.34

    10.58742/bmj.v1i2.34CrossrefPubMedScopusGoogle Scholar

  11. Baas, P., et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 2021. 397(10272): p. 375-386. doi:10.1016/S0140-6736(20)32714-8

    10.1016/S0140-6736(20)32714-8CrossrefPubMedScopusGoogle Scholar

  12. Maio, M., et al., Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology, 2017. 18(9): p. 1261-1273. doi:10.1016/S1470-2045(17)30446-1

    10.1016/S1470-2045(17)30446-1CrossrefPubMedScopusGoogle Scholar

  13. Calabrò, L., et al., Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018; 6 (6): 451–60. doi:10.1016/S2213-2600(18)30151-6

    10.1016/S2213-2600(18)30151-6CrossrefPubMedScopusGoogle Scholar

  14. Rohatgi, A. and J.M. Kirkwood, Beyond PD-1: the next frontier for immunotherapy in melanoma. Frontiers in Oncology, 2021. 11: p. 640314. doi:10.3389/fonc.2021.640314

    10.3389/fonc.2021.640314CrossrefPubMedScopusGoogle Scholar

  15. Bagge, R.O., et al., The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021. 31(2): p. 181-185. doi:10.1097/CMR.0000000000000719

    10.1097/CMR.0000000000000719CrossrefPubMedScopusGoogle Scholar

  16. Alley, E.W., et al., Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology, 2017. 18(5): p. 623-630. doi:10.1016/S1470-2045(17)30169-9

    10.1016/S1470-2045(17)30169-9CrossrefPubMedScopusGoogle Scholar

  17. Popat, S., et al., A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 2020. 31(12): p. 1734-1745. doi:10.1016/j.annonc.2020.09.009

    10.1016/j.annonc.2020.09.009CrossrefPubMedScopusGoogle Scholar

  18. Gemelli, M., et al., Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis. Cancers, 2022. 14(24): p. 6063. doi:10.3390/cancers14246063

    10.3390/cancers14246063CrossrefPubMedScopusGoogle Scholar

  19. Antonia, S., et al., Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer. The Lancet. Oncology, 2016. 17(3): p. 299. doi:10.1016/S1470-2045(15)00544-6

    10.1016/S1470-2045(15)00544-6CrossrefPubMedScopusGoogle Scholar

  20. Calabrò, L., et al., Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. The Lancet Respiratory Medicine, 2018. 6(6): p. 451-460. doi:10.1016/S2213-2600(18)30151-6

    10.1016/S2213-2600(18)30151-6CrossrefPubMedScopusGoogle Scholar

  21. Larkin, J., et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England journal of medicine, 2015. 373(1): p. 23-34. doi:10.1056/NEJMoa1504030

    10.1056/NEJMoa1504030CrossrefPubMedScopusGoogle Scholar

  22. Rizvi, N.A., et al., Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA oncology, 2020. 6(5): p. 661-674. doi:10.1001/jamaoncol.2020.0237

    10.1001/jamaoncol.2020.0237CrossrefPubMedScopusGoogle Scholar

Copyright © 2023 The Author(s)

  • Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials

    Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more

    Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination…

    2025 5,636 reads 1 citation

    doi:10.58742/bmj.v4i1.216

    Full text PDF XML

  • Pembrolizumab (Anti-PD-1) Immunotherapy in Malignant Pleural Mesothelioma: A Systematic Review of the Current Literature

    Rebaz M. Ali, Fahmi H. Kakamad, Hiwa O. Abdullah, Shalaw H. Abdulla, Shaho F. Ahmed, Bnar J. Hama Amin, Marwan N. Hassan, Sabah J. Hasan and 4 more

    Introduction Malignant pleural mesothelioma is an infrequent and aggressive type of cancer that is difficult to treat, and standard therapies have shown limited effectiveness. There have been recent advances in the development of targeted therapies for malignant pleural mesothelioma, including immunotherapy with…

    2023 1,383 reads 4 citations

    doi:10.58742/bmj.v1i2.34

    Full text PDF XML

  • Safety and Efficacy of Atezolizumab in Ovarian Cancer

    Rebaz M. Ali, Sami S. Omar, Shano M. Ali, Shvan H. Mohammed, Karokh K. Mohammed, Mohammed Q. Mustafa, Yousif M. Mahmood, Suhaib H. Kakamad and 8 more

    Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of atezolizumab remain unclear. This review aimed to evaluate the efficacy and safety profile of atezolizumab specifically. Methods PubMed/MEDLINE and…

    2026 463 reads 0 citations

    doi:10.58742/bmj.v4i2.238

    Full text PDF XML

PDF